Popular Articles

Fresh weakness likely below 17,055
Rex Cano / Mumbai December 09, 2009, 9:22 IST

L&T tumbles on fall in net
The scrip ended 3.5% lower at Rs 1,472. The counter clocked volumes of 13.97 crore as compared tp the two-week daily average traded volumes of 3.78 crore shares on the BSE.

News of the day

SAIL, NMDC to sign pact for mining limestone reserves
Two top PSUs under the steel ministry -- SAIL and NMDC -- will enter into an agreement on Monday to mine Arki Limestone Mine in Himachal Pradesh, the home state of Steel Minister Virbhadra Singh.
Online Business

Pharma ind seeks govt assistance on takeover concerns

Concerned over the recent takeover of some firms by Multi National Companies (MNCs), the domestic pharmaceutical industry has asked the government to protect and promote it by making available funds for research and development. - CBI seeks govt nod for full probe on Sibal - NCP, Cong meet to resolve portfolio sharing - Govt mulls PSU disinvestment piggyriding on FPOs - Stimulus to stay; may cut oil, fert subsidies: FM - NCP ready to support Maha govt from outside: Bhujbal - Govt to contest EU"s probe on steel fasteners In a letter to the department of pharmaceuticals, Indian Pharmaceutical Alliance (IPA) has said lack of available funding is the main reason for the recent spurt in the sale of stakes in domestic companies. "In view of your concern and interest in promoting growth and development of pharmaceutical industry, we urge you to examine this phenomenon and consider appropriate funding mechanism to protect and promote the domestic industry," IPA said. Since June last year, multinationals have acquired six drug comopanies, including the Rs 22,000 crore takeover of Ranbaxy Laboratories by Japanese drug maker Daiichi Sankyo. According to industry experts, drying up of product pipelines of MNCs are forcing them to buy up Indian firms to a get a hold on the generic business globally. Of late, there have been reports of majors like Pfizer scouting the Indian market for acquisitions. The association said the sell-outs have highlighted the need for an "appropriate funding mechanism" to meet the challenges faced by Indian pharma companies. Also, these have exposed the limitations of the current policy framework of providing weighted deduction for R&D and meagre amounts granted under Market Development Assistance (MDA) programme, it said.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):